Penumbra, Inc. Overview
Pro stress-test →Penumbra is a thrombectomy company focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, and acute limb ischemia. The company designs, manufactures, and markets thrombectomy and embolization devices to mechanically remove blood clots, selling mainly to hospitals and physicians.
Strategic Profile
Pro stress-test →Penumbra is described as the world's leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. Boston Scientific has agreed to buy Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Competitive Landscape
Pro stress-test →Main competitors include Boston Scientific Corp and Stryker Corp. Penumbra maintains differentiation through its proprietary aspiration-based CAVT technology and comprehensive product portfolio spanning neurovascular and peripheral markets. The market is characterized by innovation-driven competition in minimally invasive vascular interventions.
Industry Context
Penumbra, Inc. operates in Medical Devices - Neurovascular & Cardiovascular Interventions.
Key facts
Founded: 2004 · Headquarters: Alameda, US · Employees: 4,500 · Revenue: $1.40B · Market cap: $13.3B